Quantcast
Last updated on April 24, 2014 at 12:40 EDT

Latest OLYSIO Stories

2013-11-25 04:21:07

OLYSIO(TM) is the first once-daily protease inhibitor approved for the treatment of chronic hepatitis C in a combination antiviral regimen for adults with compensated liver disease TITUSVILLE, N.J., Nov. 25, 2013 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved OLYSIO((TM)) (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an...

2013-11-22 20:22:56

OLYSIO(TM) is the first once-daily protease inhibitor approved for the treatment of chronic hepatitis C in a combination antiviral regimen for adults with compensated liver disease TITUSVILLE, N.J., Nov. 22, 2013 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved OLYSIO((TM)) (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an...